bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.10.09.758060

Positive selection and structural disruption of KCNA5 by mutation in colorectal cancer

Abstract

Ion channels regulate cell proliferation, survival and migration, but the functional consequences of many ion channel mutations in cancer are unknown, and electrophysiological characterisation at scale is impractical. Here we use the mutational landscape of colorectal adenocarcinoma as a functional filter to identify potassium channel mutations under selection. A dN/dS screen of 16 potassium channels expressed in the large intestine identified KCNA5 (Kv1.5) as the strongest candidate under positive mutational selection. These mutations cluster in the T1 tetramerisation, S1-S4 voltage-sensor and pore domains, yet avoid the selectivity filter, indicating that selection does not favour loss of conduction. Within the pore region, the observed mutations occupy a biophysical space distinct from known C-type inactivation, activation-gate and toxin-binding mutations. In the voltage sensor, mutations affect gating-charge arginines. In the T1 domain, mutations fall on inter-subunit interfaces conserved across the KCNA family, and saturation mutagenesis energy calculations predict that they destabilise subunit contacts or the folding of the domain. Molecular dynamics simulations of D166N and G128R show loss of coordinated interface dynamics and distortion of the local backbone, respectively. Transcriptomic analysis of KCNA5-mutant tumours shows reduced expression of cell-cycle, KRAS-related and inflammatory pathways, and we observe differences between transcriptional effects induced by T1 and S1-S4 domain mutations. These changes are not reproduced by low KCNA5 expression alone, consistent with an effect specific to the mutant protein. Together, these computational results highlight that KCNA5 is under mutational selection in colorectal adenocarcinoma, and that these mutations are likely functional and induce phenotypic effects on tumors.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Xu, B., Shorthouse, D.. 2026-10-12. Positive selection and structural disruption of KCNA5 by mutation in colorectal cancer. https://doi.org/10.64898/2026.10.09.758060

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Spatial epigenomics reveals ancestry-associated regulatory states linked to aggressive prostate cancer biology

Prostate cancer (PCa) exhibits substantial biological heterogeneity, including population associated differences in tumor aggressiveness and clinical outcomes. Although socioeconomic and environmental factors contribute to these disparities, intrinsic tumor regulatory programs may also influence disease behavior. Here, we investigated whether differences in chromatin regulation contribute to distinct tumor states in Black and White men with localized PCa. We performed spatial chromatin accessibility profiling (ATAC-seq) of prostatectomy specimens from Black and White patients receiving equal healthcare access at the Center for Prostate Disease Research (USUHS) and Walter Reed National Military Medical Center. Tumors showed distinct chromatin accessibility landscapes between the two populations, with tumors from Black patients exhibiting reduced accessibility of motifs associated with the chromatin architectural regulator CTCF and enrichment of motifs linked to epithelial-mesenchymal transition and inflammatory programs. Reduced CTCF expression was independently validated by immunohistochemistry in 99 prostatectomy specimens. These findings identify population-associated differences in chromatin regulation in localized PCa and suggest that altered CTCF-associated regulation, inflammatory signaling, and epithelial plasticity may contribute to the biological heterogeneity underlying ancestry-dependent PCa disparities.

cancer biology↗

Domain-resolved epitope mapping of B7-H3-targeting VHH-Fcs defines isoform-selective binders for antibody-drug conjugate development

The immune checkpoint molecule B7-H3 has emerged as one of the most actively pursued therapeutic targets in solid tumors, and multiple B7-H3-targeting antibody-drug conjugates have entered clinical evaluation. B7-H3 occurs as a 2Ig isoform carrying a single IgV-IgC domain pair and a predominant 4Ig isoform carrying two tandem pairs of near-identical sequence in their extracellular domains. Resolving which pair an antibody engages, or how antibodies distinguish the two isoforms, requires epitope mapping at residue level. Here we generated a panel of six B7-H3-targeting VHH-Fcs and characterized them by surface plasmon resonance, epitope binning, domain-resolved deep mutational scanning and receptor internalization, benchmarked against the clinically advanced antibodies ifinatamab, mirzotamab and vobramitamab. Most VHH-Fcs bound the membrane-proximal pair more tightly than the distal pair, and 4Ig 10- to 100-fold more tightly than 2Ig, whereas the three clinical antibodies showed no such discrimination. Displaying each domain pair independently on yeast identified the residues that account for this selectivity. Internalization varied several-fold among binders, including between VHH-Fc 620 and 636, which have near-identical footprints and comparable affinities. VHH-Fc 620 internalized most efficiently, also compared to ifinatamab, and was conjugated to exatecan through a protease-cleavable linker. The conjugate showed B7-H3-dependent cytotoxicity that scaled with B7-H3 cell surface density, though it was less potent than ifinatamab-exatecan. Affinity, epitope and internalization therefore behaved as independent characteristics rather than integrating to predict antibody-drug conjugate potency. Together, these results define the molecular basis for isoform-selective recognition of B7-H3 and identify VHH-Fc 620 as a starting point for isoform-selective targeting.

cancer biology↗

Bioenergetic and Proteomic Profiling of ARID1A-Deficient Ovarian Clear Cell Carcinoma under Metabolic Challenge

ARID1A loss is associated with increased mitochondrial respiration in ovarian clear cell carcinoma (OCCC), but whether this phenotype is maintained under metabolic challenge remains unclear. Here, we examined mitochondrial function and electron transport chain (ETC) protein abundance in isogenic ARID1A wild-type (WT) and ARID1A-knockout (KO) OCCC cells cultured under physiological glucose, galactose, or the Complex I inhibitor IACS-010759. Across all conditions, KO cells maintained higher basal, ATP-linked, and maximal respiration, greater spare respiratory capacity, and higher coupling efficiency than WT cells, despite lower steady-state ATP levels. In human OCCC tumors, ARID1A-negative cases showed a higher bioenergetic cellular (BEC) index than ARID1A-positive cases, and high BEC was associated with poorer cancer-specific survival. Quantitative proteomics revealed a trend toward higher ETC complex abundance in KO cells, although whole-complex differences did not reach statistical significance. ARID1A loss was associated with selective increases in Complex III and V proteins, whereas metabolic challenge was associated with increases in Complex I and IV proteins. Together, these findings show that the ARID1A-associated mitochondrial phenotype persists across distinct metabolic challenges and is not explained simply by coordinated increases in ETC protein abundance. The association of mitochondrial bioenergetics with clinical outcomes further supports its relevance in human OCCC.

cancer biology↗